Literature DB >> 10565590

An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance. North American Diastat Group.

W G Mitchell1, J A Conry, P K Crumrine, R L Kriel, J J Cereghino, L Groves, W E Rosenfeld.   

Abstract

PURPOSE: To assess safety of diazepam rectal gel (DZPRG) for control of acute seizures in epilepsy patients and to evaluate tolerance with repeated use of DZPRG at intervals of > or =5 days.
METHODS: Subjects were persons with epilepsy, age 2 years or older, with seizure clusters or prolonged seizures. Onset of a treatable episode was defined; caregivers were trained to administer DZPRG and to monitor respiration, seizures, and adverse effects (AEs). DZPRG was dispensed in a single-use, prefilled syringe; dosage was determined by age and weight. Maximal use was > or =5-day intervals, < or =5 times/month. After use, caregivers returned data booklets and syringe. Caregivers and physicians completed global ratings yearly.
RESULTS: In 149 subjects treated, 77% of 1,578 administrations resulted in seizure freedom for the next 12 h. One hundred twenty-five received two or more treatments (two to 78; median, 8), 0.03-4.3/month (median, 0.4). To evaluate tolerance, subjects with two or more episodes were divided into low (two to seven episodes) and high use (eight to 78 episodes treated). There was no difference in proportion seizure free 12 h after the first administration versus last administration, for either infrequent or frequent administration. Sedation occurred in 17%, attributed to DZPRG in 9%. No respiratory depression was attributable to DZPRG. Three subjects withdrew because of AEs attributable to (agitation) or possibly attributable to DZPRG (chest pain, rash). Five subjects withdrew because of AEs unrelated to DZPRG. Caregiver and physician global ratings were highly positive at both 12 and 24 months.
CONCLUSIONS: DZPRG is safe and effective in children and adults with epilepsy with breakthrough seizures. Neither tolerance nor significant medication-related AEs were seen with repeated DZPRG administration at intervals > or =5 days.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565590     DOI: 10.1111/j.1528-1157.1999.tb02047.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

1.  Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study.

Authors:  Michael J Lamson; Diane Sitki-Green; Gerald L Wannarka; Michael Mesa; Paul Andrews; John Pellock
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  The Role of Benzodiazepines in the Treatment of Epilepsy.

Authors:  Juan G Ochoa; William A Kilgo
Journal:  Curr Treat Options Neurol       Date:  2016-04       Impact factor: 3.598

Review 3.  Prevention and management of febrile seizures.

Authors:  R J Baumann
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.

Authors:  James W Wheless; Ian Miller; R Edward Hogan; Dennis Dlugos; Victor Biton; Gregory D Cascino; Michael R Sperling; Kore Liow; Blanca Vazquez; Eric B Segal; Daniel Tarquinio; Weldon Mauney; Jay Desai; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia       Date:  2021-08-21       Impact factor: 6.740

Review 5.  Safety of Diastat, a rectal gel formulation of diazepam for acute seizure treatment.

Authors:  John M Pellock
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction.

Authors:  Matthew J Rogalski; Susan Kellogg-Spadt; Amy R Hoffmann; Jennifer Y Fariello; Kristene E Whitmore
Journal:  Int Urogynecol J       Date:  2010-01-12       Impact factor: 2.894

7.  Identification and treatment of acute repetitive seizures in children and adults.

Authors:  James J Cereghino
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

Review 8.  Rescue therapies for seizure emergencies: current and future landscape.

Authors:  Debopam Samanta
Journal:  Neurol Sci       Date:  2021-07-16       Impact factor: 3.830

9.  Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study.

Authors:  Michael R Sperling; James W Wheless; R Edward Hogan; Dennis Dlugos; Gregory D Cascino; Kore Liow; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia       Date:  2022-02-02       Impact factor: 6.740

10.  Consistent safety and tolerability of Valtoco® (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study.

Authors:  Ian Miller; James W Wheless; Robert E Hogan; Dennis Dlugos; Victor Biton; Gregory D Cascino; Michael R Sperling; Kore Liow; Blanca Vazquez; Eric B Segal; Daniel Tarquinio; Weldon Mauney; Jay Desai; Adrian L Rabinowicz; Enrique Carrazana
Journal:  Epilepsia Open       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.